PMID- 1714791
OWN - NLM
STAT- MEDLINE
DCOM- 19910925
LR  - 20190619
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 68
IP  - 6
DP  - 1991 Sep 15
TI  - Secondary myelodysplastic syndrome complicating therapy for osteogenic sarcoma.
PG  - 1373-5
AB  - A 12-year-old girl with nonmetastatic osteogenic sarcoma received treatment with 
      doxorubicin, methotrexate, cisplatin, cyclophosphamide, bleomycin, and 
      dactinomycin. She developed unexplained persistent pancytopenia after completion 
      of chemotherapy. Twenty-three months after the initial diagnosis of osteosarcoma 
      an evaluation revealed a bone marrow pattern consistent with the diagnosis of 
      refractory anemia with excess blasts, and karyotype analysis showed 
      characteristic findings of therapy-related myelodysplasia (loss of chromosomes 5 
      and 7, as well as 12p and 17p deletions). Bone marrow transplantation from an 
      human leukocyte antigen (HLA)-compatible sibling donor was performed 26 months 
      after the diagnosis of the primary malignancy. Although it is unproven that the 
      alkylating agents administered to this patient were responsible for the 
      myelodysplastic syndrome, careful follow-up of osteosarcoma patients who receive 
      alkylating agents is warranted.
FAU - Pappo, A
AU  - Pappo A
AD  - Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas 
      75235-9063.
FAU - Schneider, N R
AU  - Schneider NR
FAU - Sanders, J M
AU  - Sanders JM
FAU - Buchanan, G R
AU  - Buchanan GR
LA  - eng
GR  - P01 CA33625/CA/NCI NIH HHS/United States
GR  - T32 CA09640/CA/NCI NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 11056-06-7 (Bleomycin)
RN  - 1CC1JFE158 (Dactinomycin)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - Q20Q21Q62J (Cisplatin)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use
MH  - Bleomycin/administration & dosage
MH  - Child
MH  - Cisplatin/administration & dosage
MH  - Cyclophosphamide/administration & dosage
MH  - Dactinomycin/administration & dosage
MH  - Doxorubicin/administration & dosage
MH  - Female
MH  - Humans
MH  - Methotrexate/administration & dosage
MH  - Myelodysplastic Syndromes/*chemically induced
MH  - Osteosarcoma/*drug therapy
RF  - 24
EDAT- 1991/09/15 00:00
MHDA- 1991/09/15 00:01
CRDT- 1991/09/15 00:00
PHST- 1991/09/15 00:00 [pubmed]
PHST- 1991/09/15 00:01 [medline]
PHST- 1991/09/15 00:00 [entrez]
AID - 10.1002/1097-0142(19910915)68:6<1373::aid-cncr2820680631>3.0.co;2-s [doi]
PST - ppublish
SO  - Cancer. 1991 Sep 15;68(6):1373-5. doi: 
      10.1002/1097-0142(19910915)68:6<1373::aid-cncr2820680631>3.0.co;2-s.